Bottom line
This three-component set is marketed as "Coremend," "Recovery Blend," and in some listings "Wolverine Plus." Those names are not standards: observed listings claim different amounts, and other sellers use "Wolverine Plus" for a different set containing GHK-Cu instead of KPV. No published combination-specific study was identified.
No established or recommended human dose. Reported amounts below are market observations, not guidance.
Name and formulation variability
| Observed source/date | Claimed components | Claimed amounts | Verification limits |
|---|---|---|---|
| Peptide Plugs, "Wolverine Plus" (2026) | GHK-Cu, BPC-157, TB-500 | 25 / 10 / 10 mg | Incompatible GHK-Cu substitution under the adjacent name; vendor-declared only |
| Protide Health and Uther Peptide, "Coremend" (2026) | BPC-157, TB-500, KPV | 10 / 10 / 10 mg or unstated | Vendor-declared; amounts are not consistent across the name |
| Behuemn, "Recovery Blend" (2026) | BPC-157, TB-500, KPV | Unstated | Clinic marketing observation; composition not independently verified |
"Wolverine Plus" is especially unstable: the suffix may indicate added KPV or added GHK-Cu depending on the seller. See also Wolverine.
Component evidence
| Component | Separate evidence | Evidence for combination | Compatibility/stability evidence |
|---|---|---|---|
| BPC-157 | See component monograph; it does not establish performance of this mixture | None identified for this three-component set | None identified |
| TB-500 | See component monograph; identity ambiguity is material | None identified for this three-component set | None identified |
| KPV | See component monograph | None identified for this three-component set | None identified |
Combination-specific studies
No published peer-reviewed study of the exact BPC-157 + TB-500 + KPV combination was identified. The cited pages are low-quality market observations, not clinical or compatibility evidence.
Safety and interaction uncertainties
No combination-specific human safety, pharmacokinetic, toxicology, or interaction dataset was identified.
A fixed marketed mixture prevents attribution of an unexpected effect to one component.
TB-500 identity ambiguity and the name-level KPV/GHK-Cu substitution make label interpretation uncertain.
Sterility, identity, purity, and co-formulation stability cannot be inferred from a listing.
Regulatory and product-quality notes
The marketed name is not a regulatory or pharmacopoeial standard.
The cited vendor and clinic pages establish only that the names and claimed formulations are marketed.
A "research use only" description does not establish approval, safety, sterility, authenticity, or suitability for human use.
Evidence gaps
No controlled comparison of the blend with its components
No independent identity or content verification across observed names
No published compatibility or stability study
No standard definition of "Wolverine Plus," "Coremend," or "Recovery Blend"
Sources
Peptide Plugs. Wolverine Plus product page. https://peptideplugs.com/product/wolverine_plus/ accessed 2026-08-08.
Protide Health. Coremend TB-500/BPC-157/KPV product page. https://protidehealth.com/product/coremend-tb500-bpc157-kpv accessed 2026-08-08.
Uther Peptide. Coremend product page. https://utherpeptide.com/product/coremend/ accessed 2026-08-08.
Behuemn. Recovery Blend clinic page. https://behuemn.com/peptide-therapy/recovery-blend accessed 2026-08-08.